ABSTRACT
Background and Aims Alcohol consumption is an inherent feature of alcohol use disorder (AUD), and drinking characteristics may be diagnostically informative. This study had three aims: (1) to examine the classification accuracy of several drinking quantity/frequency indicators in a large representative sample of U.S. community adults; (2) to extend the findings to a clinical sample of adults; and (3) to examine potential sex differences.
Design This retrospective study utilized receiver operating characteristic (ROC) curves to evaluate area under the curve (AUC). Optimal cut-offs were identified using the Youden Index. Diagnostic validity was evaluated using accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).
Measurements Index tests included measures of quantity/frequency (e.g., drinks/drinking day, largest drinks/drinking day, number of drinking days, and heavy drinking frequency). The reference standard was AUD status as determined via a clinical interview (community sample) or a symptom checklist (clinical sample).
Setting and Participants Two samples were examined: A large, nationally representative random sample of U.S. community adults who reported past-year drinking (N=25,778, AUD=20%) and a consecutive drinking clinical sample from a Canadian mental health and addictions inpatient treatment centre (N=1,341, AUD=82%).
Findings All drinking indicators performed much better than chance at classifying AUD (AUCs=0.60-0.92, ps<.0001). Heavy drinking frequency indicators performed optimally in both the community (AUCs=0.78-0.87; accuracy=0.72-0.80) and clinical (AUC=0.85-0.92; accuracy =0.77-0.89) samples. Collectively, the most discriminating drinking behaviors were heavy drinking episodes and exceeding NIAAA drinking low-risk guidelines. No substantive sex differences in optimal cut-offs or variable performance were observed.
Conclusions Drinking patterns performed well at classifying AUD in both a nationally representative and large inpatient sample, robustly identifying AUD at rates much better than chance and above accepted benchmarks, with limited differences by sex. Findings broadly support the potential utility of quantitative drinking indicators as being diagnostically informative in clinical settings.
Competing Interest Statement
James MacKillop is a principal in BEAM Diagnostics, Inc. and has served as a consultant to Clairvoyant Therapeutics. No other authors have disclosures.
Funding Statement
Funding to support this work was provided by the Peter Boris Chair in Addictions Research, a Canada Research Chair in Translational Addiction Research (CRC-2020-00170), and Homewood Research Institute, a registered charity.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Regional Centre for Excellence in Ethics, Research Ethics Board in Guelph, Ontario, Canada gave ethical approval for this work (protocol #19-8).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding Acknowledgments: Funding to support this work was provided by the Peter Boris Chair in Addictions Research, and a Canada Research Chair in Translational Addiction Research (CRC-2020-00170)
DOI: James MacKillop is a principal in BEAM Diagnostics, Inc. and has served as a consultant to Clairvoyant Therapeutics.
Data Availability
Data produced in the present study may be made available upon reasonable request to the authors